You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NTRK fusion

Showing 1 - 25 of 1,537
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer

Recruiting
  • Thyroid Cancer
  • NTRK fusion assessment
  • Roma, Italy
    Regina Elena National Cancer Institute
Mar 31, 2023

Learn More About NTRK Gene Fusion Positive in Solid Tumor in

Not yet recruiting
  • Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
  • No Drug
  • Multiple Locations, Japan
    Many Locations
Mar 20, 2023

Advanced Solid Tumors Harboring NTRK Fusion, Primary CNS Tumors Harboring NTRK Fusion Trial in Guangzhou (ICP-723)

Recruiting
  • Advanced Solid Tumors Harboring NTRK Fusion
  • Primary Central Nervous System Tumors Harboring NTRK Fusion
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Feb 16, 2023

Called VICTORIA to Learn More About How Well Larotrectinib Works

Active, not recruiting
  • Solid Tumors Harboring NTRK Fusion
  • Larotrectinib(Vitrakvi, BAY2757556)
  • Data on other treatments
  • Whippany, New Jersey
    Bayer
Aug 22, 2022

NTRK Gene Fusion - Positive Advanced or Recurrent Solid

Recruiting
  • Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
  • Larotrectinib (Vitrakvi, BAY2757556)
  • Multiple Locations, Japan
    Many locations
Jan 20, 2023

Solid Tumors Harboring NTRK Fusion Trial (Selitrectinib (BAY2731954))

No longer available
  • Solid Tumors Harboring NTRK Fusion
  • Selitrectinib (BAY2731954)
  • (no location specified)
Sep 8, 2021

Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor Trial in Australia, Korea, Republic of, United

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • Santa Monica, California
  • +11 more
Jul 27, 2022

NTRK Family Gene Mutation Trial in Germany

Recruiting
  • NTRK Family Gene Mutation
    • Berlin, Germany
    • +22 more
    Jan 18, 2023

    A Retro-/Prospective, Non-interventional, Cohort Study in Adult

    Active, not recruiting
    • Solid Tumor, Adult
    • +2 more
      • Amiens, France
      • +3 more
      Jul 22, 2022

      Advanced Solid Tumor Trial in Shanghai (FCN-011)

      Recruiting
      • Advanced Solid Tumor
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Aug 16, 2021

      Advanced Solid Malignant Tumors Trial in Fukuoka, Osaka, Tokyo (DS-6051b)

      Active, not recruiting
      • Advanced Solid Malignant Tumors
      • Fukuoka, Japan
      • +2 more
      Jan 18, 2022

      High Grade Glioma, Diffuse Intrinsic Pontine Glioma Trial in Worldwide (Larotrectinib, Larotrectinib surgical)

      Recruiting
      • High Grade Glioma
      • Diffuse Intrinsic Pontine Glioma
      • Aurora, Colorado
      • +17 more
      Aug 10, 2022

      Solid Tumor Trial in Beijing (AB-106)

      Recruiting
      • Solid Tumor
      • Beijing, China
        Chinese PLA General Hospital
      Jun 18, 2021

      Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)

      Recruiting
      • Locally Advanced or Metastatic Solid Tumors
      • Locally Advanced or Metastatic Non-small Cell Lung Cancer
      • XZP-5955 tablets
      • Beijing, Beijing, China
        Cancer Hospital Chinese Academy of Medical Sciences
      May 17, 2022

      NTRK Gene Fusion in Adult Brain Tumours

      Not yet recruiting
      • Glioma
      • Glioma data collection
      • Brain metastasis data collection
      • Marseille, France
        Hôpital Privé Clairval
      Aug 24, 2021

      Called EPI VITRAKVI to Compare Treatment Results in Infantile

      Completed
      • Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
      • Infantile Fibrosarcoma
      • Larotrectinib (Vitrakvi, BAY2757556)
      • Standard of Care
      • Multiple Locations, France
        Multiple Locations
      Jan 10, 2023

      Solid Tumors Harboring NTRK Fusion Trial in Worldwide (Selitrectinib (BAY2731954))

      Active, not recruiting
      • Solid Tumors Harboring NTRK Fusion
      • Selitrectinib (BAY2731954)
      • La Jolla, California
      • +28 more
      Aug 18, 2022

      Solid Tumors Harboring NTRK Fusion Trial in Worldwide (Larotrectinib (Vitrakvi, BAY2757556))

      Recruiting
      • Solid Tumors Harboring NTRK Fusion
      • Larotrectinib (Vitrakvi, BAY2757556)
      • Los Angeles, California
      • +50 more
      Jan 29, 2023

      Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

      Recruiting
      • Cancer
      • +15 more
      • Data collection and quality of life questionnaire
      • Graz, Austria
      • +40 more
      Jul 27, 2021

      Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Trial in Shanghai (SIM1803-1A)

      Recruiting
      • Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
      • Shanghai, China
        Shanghai Chest Hospital
      Jan 11, 2021

      Solid Tumors Harboring NTRK Fusion Trial in Mannheim (Selitrectinib (BAY2731954))

      Completed
      • Solid Tumors Harboring NTRK Fusion
      • Selitrectinib (BAY2731954)
      • Mannheim, Baden-Württemberg, Germany
        CRS Clinical-Research-Services Mannheim GmbH
      Dec 28, 2020

      Solid Tumors Harboring NTRK Fusion Trial in Glendale, Baltimore (Selitrectinib (BAY2731954) Adult tablet, Selitrectinib

      Completed
      • Solid Tumors Harboring NTRK Fusion
      • Selitrectinib (BAY2731954) Adult tablet
      • +3 more
      • Glendale, California
      • +1 more
      Aug 24, 2021

      Solid Tumors Harboring NTRK Fusion Trial in United States (Larotrectinib (Vitrakvi, BAY2757556))

      Completed
      • Solid Tumors Harboring NTRK Fusion
      • Larotrectinib (Vitrakvi, BAY2757556)
      • Aurora, Colorado
      • +7 more
      May 11, 2021

      Tumors Harboring NTRK Fusion Trial (Larotrectinib (Vitrakvi, BAY2757556))

      Approved for marketing
      • Tumors Harboring NTRK Fusion
      • Larotrectinib (Vitrakvi, BAY2757556)
      • (no location specified)
      Dec 18, 2019

      Solid Tumors Harboring NTRK Fusion Trial in Worldwide (BAY2757556 (Larotrectinib, Vitrakvi))

      Recruiting
      • Solid Tumors Harboring NTRK Fusion
      • BAY2757556 (Larotrectinib, Vitrakvi)
      • Palo Alto, California
      • +158 more
      Aug 8, 2022